A leading prescription brand had lost market share following negative publicity. With local key opinion leaders questioning the brand’s efficacy, both medical and consumer media were running hard with the story – eroding prescriber and patient trust. The client needed a powerful tool to support its omnichannel response and quickly turn this around.
Exclusive AusDoc survey. What you will learn from reading this article: Doctors are experiencing increased patient demand for medicinal cannabis, but most acknowledge a lack of knowledge about risks and benefits and are unsure how to advise patients, says a 2021 meta-analysis of 21 international articles. Fast-forward to 2023 and not much has changed, according
Exclusive AusDoc survey. What you will learn from reading this article: Doctors have little knowledge of medicinal cannabis brands, according to the results of an AusDoc survey involving more than 240 GPs and specialists across Australia. In a finding that leaves space wide open for marketers to build their brand equity, 77% of survey respondents
Medical Affairs professionals must demonstrate digital competency and mindset change to continue benefiting from the Covid-19 digital transformation, according to an opinion article by Daniel Furtner and colleagues. They write that engagement of the future will need to be high quality and tailored to individual doctors’ needs and preferences. And digital tools will replace many
The large canvas offered by print makes it the billboard of S4 marketing. And that billboard is becoming increasingly dynamic, thanks to the ubiquitous QR code. Print advertising has ridden the wave of digital disruption to remain an integral part of the pharmaceutical omnichannel marketing mix. “Clever marketers are using print in a different way.
With many GPs no longer seeing sales representatives, pharmaceutical companies should be prepared to engage and support GPs under a digitally led model.
COVID-19 created opportunities for pharmaceutical companies to find new ways to engage with GPs. While face-to-face rep visits are likely to remain integral, it’s clear that increasingly time-poor GPs are seeking synthesised, relevant insights in a timely manner and want to drive the engagement on their terms.
With the TGA having registered 99 new medicines so far in 2024 (as at 26/09/2024) and the PBS updating its schedule several times a year, we explored how GPs prefer to find out about new medicines. According to one study, GPs are unlikely to spontaneously go looking for information about new medicines. Instead, they are
Given the scripted nature placed on pharma sales reps and their communication with doctors, do new technologies such as chat bots create the opportunity to deliver these messages in a better way? Chatbots can provide a convenient and cost-effective way for doctors and pharma sales reps to communicate, enabling doctors to access the product information
Do you want to boost your lead generation and increase GP touchpoints 6-fold? The new Access.PLUS Sample and Service requests package has already proved itself with 2,000+ doctor lead generations and 3,000+ sample requests for 10 pharma companies. The package is designed to improve the efficiency of your field force by generating more touchpoints for
GPs have a low understanding of the difference between medical science liaisons (MSLs) and pharmaceutical sales reps, according to a recent survey conducted by AusDoc.1 The finding is unsurprising, given that MSLs generally focus on other specialists. But the increasing complexity of GP work means they will likely receive increasing MSL attention in the future.
The recent Veeva Pulse Field Trends Report 2Q22[i] provided valuable insight into when, where and how field teams and healthcare professionals interact with the pharmaceutical industry representatives. However, the global report didn’t’ offer any Australia-specific findings. To fill this gap, Inside Healthcare conducted a similar study among AusDoc’s extensive GP database to provide deeper insights